They showed that higher PD-1 expression on CD8+ TILs reflects the interaction with tumor antigens and can be considered a predictive biomarker for delivering therapeutic antibodies able to disrupt the PD-1/PD-L1 interaction [27]. This evidence concerns the gene CD8A and neoplasm.